Ignite Creation Date:
2024-05-05 @ 11:54 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00178607
Status:
COMPLETED
Last Update Posted:
2016-05-12
First Post:
2005-09-12
Brief Title:
Covalent Tolerance Induction to Factor VIII-Prediction of Inhibitors in Hemophilia
Sponsor:
The University of Texas Health Science Center Houston
Organization:
The University of Texas Health Science Center Houston
Study Overview
Official Title:
Covalent Tolerance Induction to Factor VIII-Prediction of Inhibitors in Hemophilia
Status:
COMPLETED
Status Verified Date:
2016-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To correlate the Human Leukocyte Antigen type and genetic defect with hemophilia A
Detailed Description:
One of the most serious complications of treatment in patients with hemophilia A or hemophilia B is the development of an inhibitor which is an antibody that neutralizes the factor VIII or IX coagulant activity Up to one fourth of patients with severe hemophilia A develop an inhibitor but at present it is not possible to predict which patients will develop such antibody The ability to predict an inhibitor development at an individual level would greatly improve therapeutic approach to this serious problem
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None